Ronan Hsieh, MD, MS
@ronanhsieh
Followers
540
Following
458
Media
55
Statuses
642
GI oncologist at @Provswedish. Trials/drug development/AI/ML. #esophageal #gastric #colon #rectal #liver #biliary #pancreatic #anal @swog GI committee.
Seattle, WA
Joined September 2010
RT @smitha42: Thrilled to be here at the #WalkToEndColonCancer with patients/ families/friends/colleagues in beautiful CLE raising 💰for #C….
0
10
0
RT @Erman_Akkus: 📣Durva-FLOT was added to NCCN guidelines of gastric and GEJ adenoca. ✅For PDL1 positive tumors, category 1.✅CPS or TAP.✅PD….
0
88
0
The most fun image & video creation tool in the world is here. Try it for free in the Grok App.
0
187
1K
RT @ArndtVogel: Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications.@Cancer_Cell ..
0
7
0
RT @pashtoonkasi: 🆕🗞️Hot off the press! @NatureMedicine. #KRAS Vaccine💉for patients with RAS➕cancers🎯. Benefit➡️durable.🙌🏽. More to come w….
0
102
0
RT @dr_yakupergun: Oxaliplatin in Stage II–III CRC: Age Matters. 🔹 Stage III, ≤70 yrs → OS benefit .🔹 Stage III, >70 yrs → No OS gain.🔹 Sta….
0
86
0
RT @changhoon_yoo: Thanks for posting our results! @ArndtVogel BTC has very diverse target profiles. Eagerly waiting for novel drugs!.
0
2
0
RT @IbrahimSahinMD1: ✳️Our paper regarding the incidence rates of RAS/RAF/PIK3CA alterations in HER2 amplified CRC is now out ❗️. ✳️ Svea,….
0
9
0
RT @CathyEngMD: Finally published @OncJournal: "Blueprint for creating an #earlyonset #colorectal #cancer program based on experiences from….
0
28
0
RT @ArndtVogel: Lenvatinib Plus Pembrolizumab + CTx vs CTx in advanced Gastroesophageal Adenocarcinoma.@JCO_ASCO .🔎….
0
11
0
RT @ArndtVogel: Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer.ESMO Gastrointestinal….
0
16
0
RT @pashtoonkasi: @SuyogCancer Also, 2 practical clinical pearls. 🧬MET is not uncommon in patients with Cancer of Unknown Primary (CUP) th….
0
3
0
RT @IbrahimSahinMD1: ✳️Excited to share our paper with Dr Richard Kim ❗️. In this paper, we summarized and elaborated on predictive biomark….
0
5
0
RT @KoheiShitara: It’s my great honor to write the editorial for the pivotal MATTERHORN study @NEJM @YJanjigianMD @ASCO More global collabo….
0
60
0
RT @LorenzaRimassa: New survival benchmark for people living with advanced #biliarytractcancer - findings in @jhepatology solidify durvalum….
eurekalert.org
In a follow-up analysis to the pivotal TOPAZ-1 study, which established the combination therapy of durvalumab (an immunotherapy drug) plus gemcitabine and cisplatin (GemCis, chemotherapy drugs) as...
0
7
0
RT @KrishanJethwa: 🚨ACCORD Trial🚨. Resected Extrahepatic CCA or Gallbladder CA. 🔍Randomized. Adjuvant CRT + Camrelizumab.vs.Observation. 🔥W….
0
45
0
RT @CAHON_hemonc: 📢 Exciting News from CAHON!. We’re proud to announce that the Journal of Hematology & Oncology (JHO)—the official journal….
0
4
0
RT @marklewismd: It's easy to recommend exercise for better overall health but I had a truly remarkable day in clinic empowering patients w….
0
78
0
RT @Dr_ElvinaA: Our meta-analysis (n=12,698).shows:.Omitting 5-FU bolus from GI chemo regimens →.✔️ No difference in PFS/OS.📉 Less grade 3–….
0
60
0
RT @ArndtVogel: NIVO + IPI vs NIVO for MSI-H/dMMR mCRC: Health-related quality of life analysis.🔎CheckMate 8HW.👉mPFS clearly improved.👉 HRQ….
0
30
0